Hypercalcemia Treatment Market, by Drug Type (Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate, and Zoledronic Acid), Calcitonin, Glucocorticoids, Denosumab, Calcimimetics, and Others), by Indication (Primary Hyperthyroidism, Hypercalcemia of Malignancy, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Mar 2022

Code : CMI3504

Pages :219

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Hypercalcemia Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

The spread of the coronavirus has had a far-reaching impact on all aspects of life around the world, including drug clinical trials. Clinical trials are the most important and necessary part of drug research and development; therefore, unlike ordinary patient diagnosis and treatment, clinical trial implementation must strictly adhere to the trial protocol, ethics, and relevant regulations in addition to the common diagnosis and treatment process. For instance, according to the article published in the Nepal Journal of Epidemiology, in September 2020, Medidata technology and solutions, a global platform that supports clinical trials, conducted an electronic survey of 9,952 trial investigator site personnel. Moreover, according to the survey results, the ability to conduct ongoing clinical trials during the COVID-19 pandemic impacted 69% of respondents, while 78% stated that this situation impacted the initiation of new trials.

Furthermore, the primary concerns raised by these survey respondents that limited their ability were subject enrollment, patient recruitment, financial losses due to study cancellation, and financial implications from delayed endpoints. Overall, these issues negatively impacted the clinical trial and drug development processes worldwide. Hence, the impact of COVID-19 is expected to hamper growth of the global hypercalcemia treatment market over the forecast period.

Global Hypercalcemia Treatment Market: Restraint

The major factor that hinder growth of the global hypercalcemia treatment market include side effects of drugs for hypercalcemia. The increasing side effects of the drugs prescribed for hyperparathyroidism which is the main cause of hypercalcemia, is expected to hamper growth of the global hypercalcemia treatment market during the forecast period. For instance, some of the common side effects of Cinacalcet, which belongs to the drug class calcimimetics include diarrhea, nausea, vomiting, myalgia (muscle pain), stomach upset, weakness, and abdominal pain.